Literature DB >> 9818052

Blood brain barrier endothelial cells express candidate amyloid precursor protein-cleaving secretases.

E R Simons1, D C Marshall, H J Long, K Otto, A Billingslea, H Tibbles, J Wells, P Eisenhauer, R E Fine, D H Cribbs, T A Davies, C R Abraham.   

Abstract

Proteolytic cleavage of the amyloid precursor protein (A beta PP) results in the generation of the amyloidogenic fragment known as amyloid beta peptide (A beta). Deposition of A beta in the brain parenchyma and cerebrovasculature is a feature of Alzheimer's disease (AD). To date, the process whereby A beta is generated and deposited remains unclear. We have previously established that activated platelets from AD patients retain more A beta PP on their surface than control platelets. We report here that an endothelial cell-derived enzyme can cleave this surface platelet A beta PP. Human blood brain barrier endothelial cells from brains of AD patients were assayed for potential A beta PP-cleaving enzymes using synthetic peptide substrates encompassing the A beta N-terminus cleavage site. A protease activity capable of cleaving A beta PP on the surface of AD platelets was noted. The A beta PP cleavage is partially inhibited by EDTA, by ZincOV, as well as by a specific inhibitor of the Zn metalloprotease E.C.3.4.24.15. Furthermore, the protease is recognized by an antibody directed against it, using immunohistochemistry, Western blot analysis and flow cytometry. The protease is not secreted, but rather resides intracellularly as well as on the surface of the endothelial cells. The data suggest that E.C.3.4.24.15 synthesized by brain endothelial cells may process the platelet-derived A beta PP, yielding fragments which could contribute to cerebrovascular A beta deposits.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818052     DOI: 10.3109/13506129809003841

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  6 in total

Review 1.  Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium.

Authors:  Livius V d'Uscio; Tongrong He; Zvonimir S Katusic
Journal:  Physiology (Bethesda)       Date:  2017-01

2.  Dysfunction of the blood-cerebrospinal fluid-barrier and N-methyl-D-aspartate glutamate receptor antibodies in dementias.

Authors:  Mandy Busse; Ralf Kunschmann; Henrik Dobrowolny; Jessica Hoffmann; Bernhard Bogerts; Johann Steiner; Thomas Frodl; Stefan Busse
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-08       Impact factor: 5.270

3.  Inactivation of BACE1 increases expression of endothelial nitric oxide synthase in cerebrovascular endothelium.

Authors:  Tongrong He; Livius V d'Uscio; Ruohan Sun; Anantha Vijay R Santhanam; Zvonimir S Katusic
Journal:  J Cereb Blood Flow Metab       Date:  2022-06-08       Impact factor: 6.960

Review 4.  Delivery of therapeutic peptides and proteins to the CNS.

Authors:  Therese S Salameh; William A Banks
Journal:  Adv Pharmacol       Date:  2014-08-22

Review 5.  Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?

Authors:  Rory J Kelleher; Roy L Soiza
Journal:  Am J Cardiovasc Dis       Date:  2013-11-01

6.  Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?

Authors:  Jian-Ming Li; Li-Ling Huang; Fei Liu; Bei-Sha Tang; Xiao-Xin Yan
Journal:  BMC Neurol       Date:  2017-08-25       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.